Cell and Gene Manufacturing and Logistics

  1. Separation Of cfDNA With An NGS Kit On Fragment Analyzer Systems 3/19/2026

    Learn how precise sizing methods reveal nucleosome patterns in cfDNA and help distinguish true signal from extraction‑related artifacts for more reliable genomic analysis.

  2. Compliance, Costs, And Site Readiness In CAR-T Clinical Trials 3/19/2026

    Navigate CAR-T trial complexity: uncover key compliance, budgeting, and site readiness strategies to ensure safe, efficient, and successful patient care.

  3. All The Ways Global Biopharma Still Grapples With Annex 1 3/19/2026

    Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.

  4. Advancing Animal Health Through Innovative Biologics 3/18/2026

    Partner supporting advanced veterinary biologics with flexible capacity, technical depth, and end‑to‑end capabilities spanning vaccines, recombinant proteins, antibodies, and next‑generation therapies.

  5. Starting Point Of Every Success Story 3/18/2026

    Reliable cell banks are essential for protecting research quality. See how expert support and structured processes help maintain cell line integrity, reduce risk, and strengthen development.

  6. Managing Operational Challenges In CAR-T Clinical Trial Logistics 3/18/2026

    Coordinating CAR-T trials means managing tight timelines, cryogenic handling, staffing gaps, and chain-of-identity risks where even small missteps can delay care.

  7. Bioprocess Training And Education 3/17/2026

    Advance from development to manufacturing with expert-led, hands-on, or virtual courses that strengthen process understanding and scale-up skills designed to support every stage of your molecule’s journey.

  8. Industry Innovators: APAC's Sharp Advanced Therapeutics Edge 3/17/2026

    APAC is rapidly advancing its role in the global therapeutics landscape, fueled by faster development models. Learn how this momentum is reshaping expectations for innovation and commercialization.

  9. Why Manufacturing Drives FDA CRLs In Cell Therapy 3/17/2026

    Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major late‑stage approval risks.

  10. 10 Questions To Ask When Choosing A Cell Therapy CDMO 3/17/2026

    A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.